HuGE Literature Finder
Records 1-7
|
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
|
A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Aug . Lheureux Stephanie, Tinker Anna V, Clarke Blaise A, Ghatage Prafull, Welch Stephen, Weberpals Johanne I, Dhani Neesha C, Butler Marcus O, Tonkin Katia, Tan Qian, Tan David S P, Brooks Kelly, Ramsahai Janelle, Wang Lisa, Pham Nhu-An, Shaw Patricia A, Tsao Ming-Sound, Garg Swati, Stockley Tracy L, Oza Amit |
|
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Investigational new drugs 2018 Apr . Aghajanian Carol, Bell-McGuinn Katherine M, Burris Howard A, Siu Lillian L, Stayner Lee-Ann, Wheler Jennifer J, Hong David S, Kurkjian Carla, Pant Shubham, Santiago-Walker Ademi, Gauvin Jennifer L, Antal Joyce M, Opalinska Joanna B, Morris Shannon R, Infante Jeffrey |
|
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Oncotarget 2017 Aug 8 (34): 57528-57536. Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
|
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Oncotarget 2017 Feb . Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
|
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Clinical colorectal cancer 2016 Mar . Bowles Daniel W, Kochenderfer Mark, Cohn Allen, Sideris Lucas, Nguyen Nghia, Cline-Burkhardt Vivian, Schnadig Ian, Choi Minsig, Nabell Lisle, Chaudhry Arvind, Ruxer Robert, Ucar Antonio, Hausman Diana, Walker Luke, Spira Alexander, Jimeno Anton |
|
A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Nov . Ma Cynthia X, Luo Jingqin, Naughton Michael, Ademuyiwa Foluso O, Suresh Rama, Griffith Malachi, Griffith Obi L, Skidmore Zachary, Spies Nicholas C, Ramu Avinash, Trani Lee, Pluard Timothy, Nagaraj Gayathri, Thomas Shana N, Guo Zhanfang, Hoog Jeremy, Han Jing, Mardis Elaine R, Lockhart A Craig, Ellis Matthew |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: